case_images: PMC10642203_01
case_images: Schema of the proposed therapy with dosages as per the STROACT protocol.
case_images: fneur-14-1269651-g0001.jpg
case_images: PMC10642203_01_fneur-14-1269651-g0001.jpg
case_images: F1
case_images: In this study, high anti-Xa activity and a short time from the last intake of NOAC before the onset of stroke (<1 h) implied the selection of a high dose of antidote (andexanet alfa or placebo) (Figure 1).